ArticleBMC biology2025
AMCL: supervised contrastive learning with hard sample mining for multi-functional therapeutic peptide prediction.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioactive peptides targeting dyslipidemia and atherosclerosis: from computational discovery and data bottlenecks to precision medicine translation.Frontiers in molecular biosciences · 2026Review
- METFAN: Multisource Enhanced Therapeutic Peptide Function Prediction via Adapter Network.ACS omega · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMulti-functional therapeutic peptides have emerged as promising candidates in drug development and disease diagnosis due to their biocompatibility, targeting capability, and low immunogenicity. However, the identification of peptide functions through wet-lab experiments is both time-consuming and costly, necessitating efficient computational prediction methods. The field faces challenges such as long-tail distribution problems, data sparsity, and complex label co-occurrence patterns due to peptides' multi-functional nature.
resultsTo address these challenges, we propose AMCL, a novel framework for multi-functional therapeutic peptide prediction. AMCL incorporates a semantic-preserving data augmentation strategy, a multi-label supervised contrastive learning mechanism with hard sample mining, and a weighted combined loss combining Focal Dice Loss (FDL) and Distribution-Balanced Loss (DBL) to alleviate class imbalance issues. Additionally, we introduce a category-adaptive threshold selection mechanism for individual functional categories. The interpretability of AMCL is demonstrated through feature space analysis and Gradient-weighted Class Activation Mapping (Grad-CAM) visualization.
conclusionsComprehensive experiments show that AMCL significantly outperforms existing methods across multiple key metrics, including Absolute true, Accuracy, Macro-F1, and Micro-F1, establishing a new state-of-the-art in therapeutic peptide multi-functional prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.